[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594342":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":21,"collaborators":10,"id":25,"slug":10,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":28,"acronym":10,"eligibilityCriteria":29,"healthyVolunteers":30,"sex":31,"minAge":32,"maxAge":10,"enrollmentInfo":33,"targetDuration":10,"studyType":36,"phases":10,"briefSummary":37,"conditions":38,"keywords":10,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":10},{"fullName":5,"class":6},"Capital Medical University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Exploration group",null,"200 participants, to explore and formulate and optimize personalized plans and standards for health examinations for people living in plateaus.",{"label":13,"type":10,"description":14,"interventionNames":10},"Verification group","100 participants, to verify the feasibility of the physical examination plan and its effectiveness in the early diagnosis of altitude sickness and plateau environment-related comorbidities.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Yuan Wang, MD","CONTACT","+86-13581567815","wilma0106@163.com",{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ji Xunming,MD,PhD","Principal Investigator","100594342",false,"NCT07018193","The Study of Personalized Health Check-up Programs and Standards for High-altitude Migrant Populations","Inclusion Criteria:\n\n* Men and women aged ≥18;\n* Those living in plains and preparing to move to the plateau for a short-term or medium-term period;\n* Can understand the research requirements and be willing to sign a written informed consent form (ICF).\n\nExclusion Criteria:\n\n* Past history of contraindicated plateau travel: such as advanced COPD (FEV₁\\\u003C30% of the expected value or requires continuous oxygen therapy), advanced cystic fibrosis (FEV₁\\\u003C30% of the expected value or requires continuous oxygen therapy), advanced restricted pulmonary disease (FEV₁\\\u003C50% of the expected value or requires continuous oxygen therapy), decompensated heart failure, high-risk pregnancy, myocardial infarction or stroke occurred within 90 days, poorly controlled epilepsy, pulmonary hypertension (PASP\\>90mmHg), sickle cell anemia, unstable angina pectoris, high-risk cerebrovascular abnormalities that have not been treated, etc.",true,"ALL","18 Years",{"count":34,"type":35},300,"ESTIMATED","OBSERVATIONAL","By using wearable devices to monitor and record the physiological data changes and health outcomes (incidence and severity of high-altitude illnesses) of high-altitude migrants at different stages (pre-entry, acute\u002Fchronic high-altitude phases, and de-acclimatization phase), and referencing previous cohort studies on high-altitude populations, the study aims to provide a basis for developing personalized health assessment protocols for high-altitude migrants. The formulated assessment protocols and standards will then be validated.",[39],"High Altitude","NOT_YET_RECRUITING","2025-06-04",{"date":43,"type":44},"2025-06-12","ACTUAL",{"date":46,"type":35},"2025-06-30",{"date":48,"type":35},"2028-12-31",{"name":5,"class":6}]